{"preliminary_commentary":{"by_channel":{"x_thread":43,"youtube":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04876313\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["nivolumab","nab-paclitaxel"]],"indication":"muscle-invasive bladder cancer","name":"NURE-Combo","nct_id":"NCT04876313","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nure-combo-nct04876313. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"NURE-Combo","arms":[{"description":"Participants received 4x3 weekly cycles of 360 mg Nivolumab + 125 mg/m\\^2 Nab-paclitaxel IV on days 1 and 8, then they had cystectomy after that partecipants received adjuvant nivolumab 360 mg IV Q3W X13 cycles","label":"Combined Drugs","type":"EXPERIMENTAL"}],"collaborators":["Bristol-Myers Squibb"],"completion_date":{"date":"2025-06","type":"ESTIMATED"},"conditions":["Muscle-Invasive Bladder Carcinoma"],"enrollment":{"count":29,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Nivolumab + Nab-paclitaxel","otherNames":["Nivolumab + Abraxane"],"type":"DRUG"},{"name":"Nivolumab","otherNames":["Adjuvant Nivolumab"],"type":"DRUG"}],"last_update":"2022-04-06","lead_sponsor":"IRCCS San Raffaele","official_title":"An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer","overall_status":"UNKNOWN","phases":["PHASE2"],"primary_completion_date":{"date":"2024-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Pathological complete response","timeFrame":"Change from Screening after radical cystectomy"}],"references":[{"citation":"Mercinelli C, Moschini M, Cigliola A, Mattorre B, Tateo V, Basile G, Cogrossi LL, Maiorano BA, Patane DA, Raggi D, Pastorino GL, Re C, Colecchia M, Luciano R, Colombo R, Brembilla G, De Cobelli F, Briganti A, Pavlick DC, Ross JS, Montorsi F, Bellone M, Necchi A. First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer. J Clin Oncol. 2024 Dec 10;42(35):4196-4205. doi: 10.1200/JCO.24.00576. Epub 2024 Sep 6.","pmid":"39241203","type":"DERIVED"}],"start_date":{"date":"2022-01-27","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)","url":"https://clinicaltrials.gov/study/NCT04876313"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nure-combo-nct04876313"}